Member Info for Fourprinces

Https://find-and-update.company-information.service.gov.uk/company/SC852715

IG

Same directors at #ALRT which has 30 bagged. First mover advantage. Tiny MC. Next #SWC.

Https://www.lse.co.uk/rns/TIR/163250000-investment-in-standard-strategies-x7c3sb6k9m6gkk0.html

Https://www.lse.co.uk/rns/BZT/mankayan-project-update-blackstone-idm-merger-fhus7rgv8utfkpo.html

Discounted NAV (50–70% risk adj.) 15p – 25p

And a 2m delayed buy from Friday to boot!

Did say

The proposed transaction, if completed, would be material to the Company and reflects the growing third-party interest in the Company's highly prospective portfolio.

Marc Sale, CEO of First Class Metals, commented:"This potential transaction is not only a strong endorsement of the underlying value in our portfolio, but also as it's a significant cash deal has the probability to be transformational for the Company. We are confident this is a pivotal moment for First Class Metals as we move decisively to unlock that value for shareholders."

Let's see.

You didn't mention the drop the following day.

Https://www.investegate.co.uk/announcement/rns/greenroc-strategic-materials-plc--groc/amitsoq-granted-strategic-project-status/8912890

Https://www.reuters.com/sustainability/climate-energy/eu-picks-13-new-critical-material-projects-including-greenland-2025-06-04/

Yup. At the beginning of May but only for strategic innovation rather than general use https://www.supplychain.nhs.uk/programmes/product-innovation-for-customers/strategy-opportunities-for-medical-technology-products/

Genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce that following on from the draft guidance issued in April 2024, the UK's National Institute for Health and Care Excellence ("NICE") has recommended in its final guidance that CYP2C19 genotyping should be used to guide clopidogrel use after Ischaemic Stroke ("IS") or Transient Ischaemic Attack ("TIA"), and that the Genedrive® CYP2C19-ID test should be used as the test of choice for point-of-care strategies. I mean that was from March...

I thought it had already been cleared for use on the NHS?

The Genedrive® CYP2C19 ID Kit rapid test is best in class, recommended by the National Institute for Health and Care Excellence ("NICE") as the rapid genotyping platform of choice for use in the NHS, with dominant health economics, wider patient group coverage, and performance shown to be superior to laboratory testing methods.

Listen to the live space on twitter and they said instis took part in the raise

Moving up... let's see if it goes bonkers

It’s Guardant Health and Roche who developed the technology.

200k buy